← Government Schemes & Missions: Industry & Infrastructure (all topics)
Biopharma SHAKTI
What it is
Strategy for Healthcare Advancement through Knowledge, Technology and Innovation - announced in Budget 2026-27 with Rs 10,000 cr over five years from FY27 to build a domestic biologics and biosimilars ecosystem
Covers R&D, manufacturing and faster trials, with 3 new NIPERs, 7 upgraded and 1,000+ accredited trial sites; targets ~5% of the global biopharma market
Impact on industries
- Shifts support from small-molecule generics, where India leads, to biologics where it is an importer - domestic biopharma is ~$9bn against a ~$60bn pharma market
- Targets trial capacity and specialist talent, not capex alone, alongside 2026 rules cutting some approval timelines from 90 to 45 working days
- Long payback - biologics take 4-7 years and sterile high-capital plants, so revenue impact is late-decade and limited to players with existing capability
- Extends the earlier National Biopharma Mission; disbursement guidelines are still being detailed, so execution is the variable